ZBiotics Secures $12 Million in Series A Funding to Expand Revolutionary Probiotic Line

ZBiotics, a trailblazer in the realm of genetically engineered probiotics, has successfully concluded its $12 million Series A funding round. The investment, led by Spring Tide Capital and supported by Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures, marks a significant milestone for the company. The funds are set to fuel ZBiotics‘ plans…

Read More

IceCure’s ProSense® Delivers 100% Success Rate in Breakthrough Cryoablation Study, Paving the Way for Non-Surgical Breast Cancer Treatment

IceCure Medical Ltd has announced a landmark achievement with its ProSense® cryoablation system, as detailed in a recent study published in the British Journal of Radiology. The study, conducted at Hospital Lucus Augusti in Lugo, Spain, demonstrates a 100% complete ablation rate for luminal A and B breast cancer tumors ≤ 25mm after a median…

Read More

Halda Therapeutics Garners $126 Million in Series B Extension to Propel Innovative Cancer Treatments into Clinical Trials

Halda Therapeutics, a leading biotechnology firm renowned for its pioneering cancer therapies, has successfully raised $126 million in a Series B extension. This latest funding round saw significant participation from premier investors, including Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital, and Taiho Ventures. Existing backers such as Canaan Partners,…

Read More
Founders Floris Engelhardt, John Vroom, Mark Bathe

Kano Therapeutics Secures $7.1 Million in Funding to Revolutionize Genetic Medicine with Non-Viral DNA Insertion

Kano Therapeutics, a forward-thinking biotechnology firm emerging from MIT, has announced the successful closure of a $7.1 million funding round, underscoring its potential to reshape the landscape of genetic medicine. This financing includes an oversubscribed $5 million seed round co-led by The Engine Ventures and VSquared Ventures, with additional support from Taihill Venture and Metaplanet….

Read More

Amulet Secures $6 Million in Series A Funding to Revolutionize Food Allergen Detection

Amulet, an innovator in food safety technology, has successfully raised $5.8 million in Series A financing. This round, spearheaded by HealthX Ventures, also saw participation from Incite Ventures, AllerFund, Mendota Venture Capital, Great Oaks Venture Capital, and notable individuals including Pinterest executive Julie Bornstein and investor Diede van Lamoen. The investment will propel Amulet’s mission…

Read More

NeuroTherapia Gains $12.3M in Series B Funding to Advance Breakthrough Alzheimer’s Treatment

NeuroTherapia, Inc., a clinical-stage biotech company and Cleveland Clinic Innovations portfolio entity, has successfully completed the first close of its Series B financing with $12.3M raised. The financing round, led by Cleveland Clinic, sees continued support from Brain Trust Accelerator Fund II, Dolby Family Ventures, and the Alzheimer’s Drug Discovery Foundation (ADDF), with new investment…

Read More
Dan Kemp CEO at Shinobi Therapeutics

Shinobi Therapeutics Receives $59M Grant from Japanese Agency for Medical Research and Development

Shinobi Therapeutics, a trailblazer in immune evasive iPS cell therapies, has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). This significant grant will accelerate the development of Shinobi’s pioneering iPS-T cell therapy, aimed at treating GPC3+ solid tumors. Dr. Yasumichi Hitoshi, Chief of…

Read More

AIRNA Secures $60 Million in Oversubscribed Financing to Propel RNA Editing Innovations

AIRNA, a cutting-edge biotech firm specializing in RNA editing therapeutics, has successfully closed an oversubscribed $60 million Series A financing round, pushing the total raised to $90 million. This investment, led by Forbion and supported by a prestigious group of investors including ARCH Venture Partners, Ono Venture Investment, Alexandria Venture Investments, and ND Capital, will…

Read More

Jade Biosciences Secures $80 Million Funding to Advance Breakthrough Therapies for Autoimmune Diseases

Jade Biosciences, a biotechnology innovator focused on autoimmune diseases, has announced the successful closing of an $80 million financing round. Led by Fairmount and Venrock Healthcare Capital Partners, with additional contributions from Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP, this investment will drive the development of Jade’s cutting-edge therapies…

Read More

LTZ Therapeutics Secures $20M Series A to Revolutionize Cancer Treatment with Cutting-Edge Myeloid Engager Technology

LTZ Therapeutics, an emerging leader in immunotherapy, has successfully completed a $20 million Series A financing round. This round, spearheaded by new investor Lapam Capital and including significant contributions from GL Ventures, K2 Venture Partners, and Shunwei Capital, brings LTZ’s total funding to approximately $50 million since its inception in 2022. The new capital will…

Read More